Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

Cited by (6,144)

Items 301–400 of 6,144

1. Sitosterolemia, Hypercholesterolemia, and Coronary Artery Disease
   Hayato Tada, Atsushi Nohara, Akihiro Inazu, Nagahiko SAKUMA, Hiroshi Mabuchi, Masa‐aki Kawashiri · 2018 · Journal of Atherosclerosis and Thrombosis
2. Cardiovascular risk in renal transplant recipients
   Paul A. Devine, Aisling E. Courtney, Alexander Peter Maxwell · 2018 · Journal of Nephrology
3. 2022 Prevention of chronic non-communicable diseases in Of the Russian Federation. National guidelines
   Oksana M. Drapkina, Концевая Анна Васильевна, А. М. Калинина, S.M. Avdeev, Агальцов Михаил Викторович, L. M. Alexandrova, А. А. Анциферова, Aronov Dm, Н. М. Ахмеджанов, Yu. А. Balanova et al. · 2022 · CARDIOVASCULAR THERAPY AND PREVENTION
4. Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
   Arai, Hidenori, Yamashita, Shizuya, Yokote, Koutaro, Araki, Eiichi, Suganami, Hideki, Ishibashi, Shun, on behalf of the K-877 Study Group · 2018 · Journal of Atherosclerosis and Thrombosis
5. Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care
   Gerald Francis Watts, Samuel S. Gidding, Pedro Mata, Jing Pang, DAVID R. SULLIVAN, Shizuya Yamashita, Frederick Johan Raal, Raul Dias Santos, Kausik Kumar Ray · 2020 · Nature Reviews Cardiology
6. Small rodent models of atherosclerosis
   Yihan Zhao, Hua Qu, Yuhui Wang, Wenli Xiao, Ying Zhang, Dazhuo Shi · 2020 · Biomedicine & Pharmacotherapy
7. Genetic association of lipids and lipid-lowering drug target genes with non-alcoholic fatty liver disease
   Ziang Li, Bin Zhang, Qing‐Rong Liu, Zhihang Tao, Lu Ding, Bo Guo, Erli Zhang, Haitong Zhang, Zhen Meng, Shuai Guo et al. · 2023 · EBioMedicine
8. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
   Kasichayanula, Sreeneeranj, Grover, Anita, Emery, Maurice G., Gibbs, Megan A., Somaratne, Ransi, Wasserman, Scott M., Gibbs, John P. · 2018 · Clinical Pharmacokinetics
9. 2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation
   О. Л. Барбараш, Dmitry Viktorovich Duplyakov, D. A. Zateischikov, Е. П. Панченко, Roman M. Shakhnovich, I. S. Yavelov, Aleksey N. Yakovlev, Abugov Sa, Bagrat G. Alekyan, Архипов Михаил Викторович et al. · 2021 · Russian Journal of Cardiology
10. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
    Peter W.F. Wilson, Tamar S. Polonsky, Michael D. Miedema, Amit Khera, Andrzej Stanislaw Kosinski, Jeffrey T. Kuvin · 2019 · Circulation
11. PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages
    Ding, Zufeng, Liu, Shijie, Wang, Xianwei, Theus, Sue, Deng, Xiaoyan, Fan, Yubo, Zhou, Sichang, Mehta, Jawahar L · 2018 · Cardiovascular Research
12. Cardiopulmonary Impact of Particulate Air Pollution in High-Risk Populations
    Jonathan D. Newman, Deepak L. Bhatt, Sanjay Rajagopalan, John Randolph Balmes, Michael D Brauer, Patrick N. Breysse, Alison G. M. Brown, Mercedes R. Carnethon, Wayne E. Cascio, Gwen W. Collman et al. · 2020 · Journal of the American College of Cardiology
13. Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES
    J. Wouter Jukema, Laurien E. Zijlstra, Deepak L. Bhatt, Vera Bittner, Rafael Díaz, Heinz Drexel, Shaun G. Goodman, Yong-Un Kim, Robert C. Pordy, Željko Reiner et al. · 2019 · Circulation
14. Ten things to know about ten cardiovascular disease risk factors – 2022
    Harold Edward Bays, Anandita Agarwala, Charles Amir German, Priyanka Satish, Adedapo Iluyomade, Ramzi Dudum, Aarti Thakkar, Mahmoud Al Rifai, Anurag Mehta, Aneesha Thobani et al. · 2022 · American Journal of Preventive Cardiology
15. Lipid lowering therapy and circulating PCSK9 concentration
    Nozue, Tsuyoshi · 2017 · Journal of Atherosclerosis and Thrombosis
16. Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm
    Seamus C. Harrison, Michael Vaclav Holmes, Stephen Burgess, Folkert Wouter Asselbergs, Gregory T. Jones, Annette F. Baas, Femke N. G. van ’t Hof, Paul I. W. de Bakker, Jan D. Blankensteijn, Janet T. Powell et al. · 2017 · JAMA Cardiology
17. Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design
    Candice Alleyne, Rupesh P. Amin, Bhavana Bhatt, Elisabetta Bianchi, J. Craig Blain, Nicolas C. Boyer, Danila Branca, Mark W. Embrey, Sookhee Ha, Kelli M. Jette et al. · 2020 · Journal of Medicinal Chemistry
18. Trends in lipid-modifying agent use in 83 countries
    Joseph E. Blais, Yue Wei, Kevin K.W. Yap, Hassan H Alwafi, Tiantian Ma, Ruth Brauer, Wallis C. Y. Lau, Kenneth K. C. Man, Chung Wah Siu, K. C. B. Tan et al. · 2021 · Atherosclerosis
19. PCSK9 inhibition and inflammation: A narrative review
    Massimiliano Ruscica, Lale S Tokgözoğlu, Alberto Corsini, Cesare Riccardo Sirtori · 2019 · Atherosclerosis
20. Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention
    Renate M. Hoogeveen, João P. Belo Pereira, Nick S. Nurmohamed, Veronica Zampoleri, Michiel J. Bom, Andrea Baragetti, S. Matthijs Boekholdt, Paul Knaapen, Kay‐Tee Khaw, Nicholas J. Wareham et al. · 2020 · European Heart Journal
21. Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention
    Paul Guedeney, Bimmer E.P.M. Claessen, Deborah N. Kalkman, Melissa B. Aquino, Sabato Sorrentino, Gennaro Giustino, Serdar Farhan, Birgit Vogel, Samantha Sartori, Gilles Montalescot et al. · 2019 · Journal of the American College of Cardiology
22. INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES"
    Ivan Ivanovich Dedov, Marina Vladimirovna Shestakova, Galina Afanas'evna Mel'nichenko, Natalya Valentinovna Mazurina, Elena Nikolaevna Andreeva, I. Z. Bondarenko, Гусова Залина Руслановна, F. K. Dzgoeva, М. С. Елисеев, Ekaterina Vladimirovna Ershova et al. · 2021 · Obesity and metabolism
23. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
    Mach, François, Baigent, Colin, Catapano, Alberico L, Koskinas, Konstantinos C, Casula, Manuela, Badimon, Lina, Chapman, M John, De Backer, Guy G, Delgado, Victoria, Ference, Brian A et al. · 2020 · European Heart Journal
24. Comparison of Methods to Estimate Low-Density Lipoprotein Cholesterol in Patients With High Triglyceride Levels
    Aparna P. Sajja, Jihwan Park, Vasanth Sathiyakumar, Bibin T. Varghese, Vincent A. Pallazola, Francoise Adeline Marvel, Krishnaji R. Kulkarni, Alagarraju Muthukumar, Parag H. Joshi, Eugenia Gianos et al. · 2021 · JAMA Network Open
25. Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations
    Aeron Small, Ashley B. Pournamdari, Giorgio E. M. Melloni, Benjamin M. Scirica, Deepak L. Bhatt, Itamar Raz, Eugene Braunwald, Robert Patrick Giugliano, Marc Steven Sabatine, Gina Marie Peloso et al. · 2024 · JAMA Cardiology
26. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
    Schmidt, Amand F, Carter, John-Paul L, Pearce, Lucy S, Wilkins, John T, Overington, John P, Hingorani, Aroon D, Casas, JP · 2020 · Cochrane Database of Systematic Reviews
27. There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness
    Michael E. Makover, Michael David Shapiro, Peter Paul Toth · 2022 · American Journal of Preventive Cardiology
28. Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function
    Rosoff, Daniel B., Bell, Andrew S., Jung, Jeesun, Wagner, Josephin, Mavromatis, Lucas A., Lohoff, Falk W. · 2022 · Journal of the American College of Cardiology
29. Dyslipidemia, Diabetes and Atherosclerosis: Role of Inflammation and ROS-Redox-Sensitive Factors
    Elham Hasheminasabgorji, Jay C. Jha · 2021 · Biomedicines
30. Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm
    Steven H J Hageman, Ailsa J. McKay, Peter Ueda, Laura H. Gunn, Tomas Jernberg, Emil Hagström, Deepak L. Bhatt, Philippe Gabríel Steg, Kristi Läll, Reedik Mägi et al. · 2022 · European Heart Journal
31. The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better
    Omar Mhaimeed, Zain Ali Burney, Stacey L. Schott, Payal Kohli, Francoise Adeline Marvel, Seth Shay Martin · 2024 · American Journal of Preventive Cardiology
32. Antiinflammatory Therapy in Clinical Care: The CANTOS Trial and Beyond
    Aaron W. Aday, Paul M. Ridker · 2018 · Frontiers in Cardiovascular Medicine
33. 2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
    Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Nan Hee Kim, Ji A Seo, Mee Kyoung Kim, Jeong Hyun Lim et al. · 2023 · Diabetes & Metabolism Journal
34. Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST – 2021
    José Carlos Nicolau, Gilson Soares Feitosa, João Luiz Fernandes Petriz, Remo Holanda de Mendonça Furtado, Dalton Bertolim Précoma, Walmor Lemke, Renato D. Lópes, Ari Timerman, José Antônio Marin‐Neto, Luiz Bezerra et al. · 2021 · Arquivos Brasileiros de Cardiologia
35. Diagnosis and Management of Stable Angina
    Parag H. Joshi, James A. de Lemos · 2021 · JAMA
36. Documento de información y consenso para la detección y manejo de la enfermedad renal crónica
    Rafael García Maset, Jordi Bover, J. Segura, Marian Goicoechea Diezhandino, Jesús Cebollada del Hoyo, Javier Escalada San Martín, Lorenzo Fácila, Javier Gamarra, José Antonio García‐Donaire, Lisardo García Matarin et al. · 2021 · Nefrología
37. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
    Writing Committee Members, Blumenthal, Roger S., Morris, Pamela B., Gaudino, Mario, Johnson, Heather M., Anderson, Timothy S., Bittner, Vera A., Blankstein, Ron, Brewer, LaPrincess C., Cho, Leslie et al. · 2026 · Circulation
38. Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study
    Ali Allahyari, Tomas Jernberg, Emil Hagström, Margrét Leósdóttir, Pia Lundman, Peter Ueda · 2020 · European Heart Journal
39. LDL-C: lower is better for longer—even at low risk
    Peter Edward Penson, Matteo Pirro, Maciej Banach · 2020 · BMC Medicine
40. Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events
    Hannes Helgason, Thjodbjorg Eiriksdottir, Magnus Orn Ulfarsson, Abhishek Choudhary, Sigrún H. Lund, Erna V. Ivarsdottir, Grímur Hjörleifsson Eldjárn, Guðmundur Einarsson, Egil Ferkingstad, Kristjan H. S. Moore et al. · 2023 · JAMA
41. A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
    Marc Ferrell, Zeneng Wang, James T. Anderson, Xinmin S. Li, Marco Witkowski, Joseph A. DiDonato, James R. Hilser, Jaana Hartiala, Arash Haghikia, Tomáš Čajka et al. · 2024 · Nature Medicine
42. A radioimmunoassay for bradykinin in plasma and synovial fluid.
    Richard C. Talamo, E Haber, K. Frank Austen · 1969 · PubMed
43. Management of diabetic dyslipidemia: An update
    Ishwarlal Jialal, Gurdeep Singh · 2019 · World Journal of Diabetes
44. Inclisiran—New hope in the management of lipid disorders?
    Dyrbuś, Krzysztof, Gąsior, Mariusz, Penson, Peter, Ray, Kausik K., Banach, Maciej · 2020 · Journal of Clinical Lipidology
45. Genetics Insights in the Relationship Between Type 2 Diabetes and Coronary Heart Disease
    Mark O. Goodarzi, Jerome I. Rotter · 2020 · Circulation Research
46. Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction
    Enas A. Enas, Basil Varkey, Thiruvinvamalai S. Dharmarajan, Guillaume Paré, Vinay Kumar Bahl · 2019 · Indian Heart Journal
47. Ischaemic stroke
    James Frederick Meschia, Thomas G. Brott · 2017 · European Journal of Neurology
48. Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial
    Miao Yu, Yong Yang, Silai Dong, Chen Zhao, Fen Yang, Yuan-Fan Yuan, Yu-Hua Liao, Shao-Lin He, Kun Liu, Fen Wei et al. · 2024 · Circulation
49. Adherence and Persistence Among Statin Users Aged 65 Years and Over: A Systematic Review and Meta-analysis
    Ofori-Asenso, Richard, Jakhu, Avtar, Zomer, Ella, Curtis, Andrea J, Korhonen, Maarit Jaana, Nelson, Mark, Gambhir, Manoj, Tonkin, Andrew, Liew, Danny, Zoungas, Sophia · 2018 · The Journals of Gerontology: Series A
50. Smart Nanomedicine to Enable Crossing Blood–Brain Barrier Delivery of Checkpoint Blockade Antibody for Immunotherapy of Glioma
    Hairong Wang, Yu Chao, He Zhao, Xiuxia Zhou, Fuyong Zhang, Zheng Zhang, Zhiheng Li, Jian Pan, Jian Wang, Qian Chen et al. · 2022 · ACS Nano
51. Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy
    Ridker, Paul M, Tuttle, Katherine R, Perkovic, Vlado, Libby, Peter, MacFadyen, Jean G · 2022 · European Heart Journal
52. Inflammation and atherosclerosis: what is on the horizon?
    Neil Ruparelia, Robin P. Choudhury · 2019 · Heart
53. Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial
    Leiter, Lawrence A., Teoh, Hwee, Kallend, David, Wright, R. Scott, Landmesser, Ulf, Wijngaard, Peter L.J., Kastelein, John J.P., Ray, Kausik K. · 2019 · Diabetes Care
54. Targeting ATP-Citrate Lyase in Hyperlipidemia and Metabolic Disorders
    Stephen L. Pinkosky, Pieter H.E. Groot, Narendra D. Lalwani, Gregory R. Steinberg · 2017 · Trends in Molecular Medicine
55. Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology
    José Tuñón, Lina Badimón, Marie‐Luce Bochaton‐Piallat, Bertrand Cariou, Mat J.A.P. Daemen, Jesús Egido, Paul Charles Evans, Imo E. Hoefer, Daniel F.J. Ketelhuth, Esther Lutgens et al. · 2018 · Cardiovascular Research
56. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS)
    Nicolas Danchin, Wael A. Almahmeed, Khalid Al‐Rasadi, Joseph Azuri, ABDELKRIM BERRAH, Carlos Alberto Cuneo, Yuri Karpov, Upendra Kaul, Meral Kayıkçıoğlu, Olena Mitchenko et al. · 2018 · European Journal of Preventive Cardiology
57. Lipids and Lipid Mediators Associated with the Risk and Pathology of Ischemic Stroke
    Anna Kłoska, Marcelina Malinowska, Magdalena Gabig‐Cimińska, Joanna Jakóbkiewicz‐Banecka · 2020 · International Journal of Molecular Sciences
58. Advances in IVUS/OCT and Future Clinical Perspective of Novel Hybrid Catheter System in Coronary Imaging
    Masafumi Ono, Hideyuki Kawashima, Hironori Hara, Chao Gao, Rutao Wang, Norihiro Kogame, Kuniaki Takahashi, Ply Chichareon, Rodrigo Modolo, Mariusz Tomaniak et al. · 2020 · Frontiers in Cardiovascular Medicine
59. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke
    Erin Ann Bohula, Nicholas Marston, Ajay K. Bhatia, Gaetano Maria De Ferrari, Lawrence A. Leiter, José Carlos Nicolau, Jeong‐Gun Park, Julia Kuder, Sabina A. Murphy, Emileigh Walsh et al. · 2025 · New England Journal of Medicine
60. The pharmacological management of metabolic syndrome
    Julie Rask Larsen, Lorena Dima, Christoph Ulrich Correll, Peter Manu · 2018 · Expert Review of Clinical Pharmacology
61. Carotid Artery Stenting
    Christopher J. White, Thomas G. Brott, William A. Gray, Donald V. Heck, Tudor G. Jovin, Sean P. Lyden, David Christopher Metzger, Kenneth Rosenfield, Gary S. Roubin, Ravish Sachar et al. · 2022 · Journal of the American College of Cardiology
62. Diabetes and Cardiovascular Disease: an Update
    Almourani, Rajaa, Chinnakotla, Bhavana, Patel, Richa, Kurukulasuriya, L. Romayne, Sowers, James · 2019 · Current Diabetes Reports
63. Platelet-derived extracellular vesicles to target plaque inflammation for effective anti-atherosclerotic therapy
    Qingle Ma, Qin Fan, Xiao Han, Ziliang Dong, Jialu Xu, Jinyu Bai, Weiwei Tao, Dongdong Sun, Chao Wang · 2020 · Journal of Controlled Release
64. The Functional Role of Lipoproteins in Atherosclerosis: Novel Directions for Diagnosis and Targeting Therapy
    Yongzheng Lu, Xiaolin Cui, Li Zhang, Xu Wang, Yanyan Xu, Zhen Qin, Gangqiong Liu, Qiguang Wang, Kang Tian, Khoon S. Lim et al. · 2022 · Aging and Disease
65. 2024 Clinical practice guidelines for Stable coronary artery disease
    О. Л. Барбараш, Yu. A. Karpov, A. V. Panov, Renat S. Akchurin, Bagrat G. Alekyan, Mikhail N. Alekhin, D. M. Aronov, GOHAR HARUTYUNYAN, Yu. N. Belenkov, Sergey Anatol'evich Boytsov et al. · 2024 · Russian Journal of Cardiology
66. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease
    Peter Paul Toth, Jamie P. Dwyer, Christopher Paul Cannon, Helen Martina Colhoun, Daniel James Rader, Ashish Upadhyay, Michael J. Louie, Andrew Koren, Alexia Letierce, Jonas Mandel et al. · 2018 · Kidney International
67. Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9
    Charles Amir German, Michael David Shapiro · 2019 · BioDrugs
68. Squalene monooxygenase: a journey to the heart of cholesterol synthesis
    Ngee Kiat Chua, Hudson W. Coates, Andrew John Brown · 2020 · Progress in Lipid Research
69. Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association
    Warden, Bruce A., Guyton, John R., Kovacs, Adrienne C., Durham, Jessica A., Jones, Laney K., Dixon, Dave L., Jacobson, Terry A., Duell, P. Barton · 2023 · Journal of Clinical Lipidology
70. Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis
    Eri Toda Kato, David A. Morrow, Jianping Guo, David D. Berg, Michael A. Blazing, Erin Ann Bohula, Marc P. Bonaca, Christopher Paul Cannon, James A. de Lemos, Robert Patrick Giugliano et al. · 2022 · European Heart Journal
71. Advancing pharmaceutical research: A comprehensive review of cutting-edge tools and technologies
    Chen, Jinghong, Lin, Anqi, Luo, Peng · 2024 · Current Pharmaceutical Analysis
72. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers
    Alejandro Arrieta, Jonathan C. Hong, Rohan Khera, Salim S. Virani, Harlan M. Krumholz, Khurram Nasir · 2017 · JAMA Cardiology
73. The Diagnosis and Treatment of Hypertriglyceridemia
    Parhofer, Klaus G., Laufs, Ulrich · 2019 · Deutsches Ärzteblatt international
74. Caffeine blocks SREBP2-induced hepatic PCSK9 expression to enhance LDLR-mediated cholesterol clearance
    Paul F. Lebeau, Jae Hyun Byun, Khrystyna Platko, Paul Saliba, Matthew A. Sguazzin, Melissa E. MacDonald, Guillaume Paré, Gregory R. Steinberg, Luke Jeffrey Janssen, Suleiman A. Igdoura et al. · 2022 · Nature Communications
75. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association
    Soffer, Daniel E., Marston, Nicholas A., Maki, Kevin C., Jacobson, Terry A., Bittner, Vera A., Peña, Jessica M., Thanassoulis, George, Martin, Seth S., Kirkpatrick, Carol F., Virani, Salim S. et al. · 2024 · Journal of Clinical Lipidology
76. Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment
    Sliz, Eeva, Kettunen, Johannes, Holmes, Michael V., Williams, Clare Oliver, Boachie, Charles, Wang, Qin, Männikkö, Minna, Sebert, Sylvain, Walters, Robin, Lin, Kuang et al. · 2018 · Circulation
77. Emerging views of statin pleiotropy and cholesterol lowering
    Dongbo Yu, James K. Liao · 2021 · Cardiovascular Research
78. Multi-omics approaches for revealing the complexity of cardiovascular disease
    Stephen F. Doran, Muhammad Arif, Simon C.C. Lam, Abdulahad Bayraktar, Hasan Türkez, Mathias Uhlén, Jan Borén, Adil Mardinoğlu · 2021 · Briefings in Bioinformatics
79. 2023 China Guidelines for Lipid Management
    Jian‐Jun Li, Shui‐Ping Zhao, Dong Zhao, Guoping Lü, Daoquan Peng, Jing Liu, Zhen‐Yue Chen, Yuan‐Lin Guo, Na‐Qiong Wu, Sheng-kai Yan et al. · 2023 · 老年心脏病学杂志：英文版
80. Untitled work
    Hlatky Mark · 2017 · 10.1016/j.jacc.2017.10.001
81. Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry
    Emmanuel Sorbets, Kim Michael Fox, Yedid Elbez, Nicolas Danchin, Paul Dorian, Roberto Ferrari, Ian Ford, Nicola Greenlaw, Paul R. Kalra, Zofia Parma et al. · 2019 · European Heart Journal
82. Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome
    Hideki Yano, Shigeo Horinaka, Toshihiko Ishimitsu · 2019 · Journal of Cardiology
83. Arteriosclerosis e inflamación. Nuevos enfoques terapéuticos
    Juan Pedro‐Botet, Elisenda Climent, David Benaiges · 2020 · Medicina Clínica
84. Evaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm
    Richard Ferraro, Jacqueline M. Latina, Abdulhamied Alfaddagh, Erin D. Michos, Michael Joseph Blaha, Steven Richard Jones, Garima V. Sharma, Jeffrey C. Trost, William E. Boden, William S. Weintraub et al. · 2020 · Journal of the American College of Cardiology
85. Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges
    Chris J. Packard, M. John Chapman, Mahendra Sibartie, Ulrich Laufs, L. Masana · 2021 · Heart
86. Lipoprotein (a) and diabetes mellitus
    Claudia Lamina, Natalie C. Ward · 2022 · Atherosclerosis
87. A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis
    Weizhi Wang, Chao Liu, Jinque Luo, Lijuan Lei, Minghua Chen, Yuyan Zhang, Ren Sheng, Yining Li, Li Wang, Xin-hai Jiang et al. · 2024 · Acta Pharmacologica Sinica
88. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
    American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, Mandeep, McCoy, Rozalina G., Balapattabi, Kirthikaa, Bannuru, Raveendhara R., Bellini, Natalie J., Bennett, Allison K., Beverly, Elizabeth A., Briggs Early, Kathaleen, ChallaSivaKanaka, Sathyavathi et al. · 2026 · Diabetes Care
89. Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life
    Jennifer G. Robinson, Kevin Jon Williams, Samuel S. Gidding, Jan Borén, Ira A. Tabas, Edward A A Fisher, Chris J. Packard, Michael J. Pencina, Zahi Adel Fayad, Venkatesh Mani et al. · 2018 · Journal of the American Heart Association
90. Coronary Artery Disease Genetics Enlightened by Genome-Wide Association Studies
    Thorsten Kessler, Heribert Schunkert · 2021 · JACC Basic to Translational Science
91. Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications
    Jacqueline T. Vuong, Ashley F. Stein-Merlob, Arash Nayeri, Tamer Sallam, Tomas G. Neilan, Eric H. Yang · 2022 · Journal of the American College of Cardiology
92. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives
    Pierandrea Vinci, Filippo Giorgio Di Girolamo, Emiliano Panizon, Letizia Maria Tosoni, Carla Cerrato, Federica Pellicori, Nicola Altamura, Alessia Pirulli, Michele Zaccari, Chiara Biasinutto et al. · 2023 · International Journal of Environmental Research and Public Health
93. Inclisiran for the Treatment of Cardiovascular Disease: the Orion Clinical Development Program
    Robert M. Stoekenbroek, David G. Kallend, Peter L. J. Wijngaard, John J.P. Kastelein · 2018 · Future Cardiology
94. Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction
    Avinainder Singh, Ankur Gupta, Bradley Collins, Arman Qamar, Keri L. Monda, David W. Biery, J. Antonio G. López, Sarah D. de Ferranti, Jorge Plutzky, Christopher Paul Cannon et al. · 2019 · Journal of the American College of Cardiology
95. LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial
    Peter S. Sever, Ioanna Gouni‐Berthold, ANTHONY C. KEECH, Robert Patrick Giugliano, Terje Rolf Pedersen, KyungAh Im, Huei Wang, Beat Knüsel, Marc Steven Sabatine, Michelle L. O’Donoghue · 2020 · European Journal of Preventive Cardiology
96. The Fauna Of British India, Including Ceylon And Burma. Hymenoptera 2. Ants And Cuckoo-Wasps.
    C. T. Bingham · 1903 · INFM-OAR (INFN Catania)
97. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
    Hagström, Emil, Steg, P. Gabriel, Szarek, Michael, Bhatt, Deepak L., Bittner, Vera A., Danchin, Nicolas, Diaz, Rafael, Goodman, Shaun G., Harrington, Robert A., Jukema, J. Wouter et al. · 2022 · Circulation
98. Genome-wide association meta-analysis identifies risk loci for abdominal aortic aneurysm and highlights PCSK9 as a therapeutic target
    Tanmoy Roychowdhury, Derek M. Klarin, Michael G. Levin, Joshua Michael Spin, Yae Hyun Rhee, Alicia C. Deng, Colwyn Ansel Headley, Noah L. Tsao, Corry Gellatly, Verena Zuber et al. · 2023 · Nature Genetics
99. Circulating non-coding RNAs in biomarker-guided cardiovascular therapy: a novel tool for personalized medicine?
    David de Gonzalo‐Calvo, Àngela Vea, Christian Bär, Jan Fiedler, Liam S. Couch, Carlos Brotons, Vicenta Llorente‐Cortés, Thomas Thum · 2018 · European Heart Journal
100. Anticalin® Proteins as Therapeutic Agents in Human Diseases
     Christine Rothe, Arne Skerra · 2018 · BioDrugs